Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2013-09-09 M&A Activity
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi förvärvar samtliga rättigheter för Kineret® samt kliniska data för Kepivance® från Amgen
M&A Activity Classification · 95% confidence The document is a press release dated September 9, 2013, announcing that Swedish Orphan Biovitrum AB (Sobi) has acquired full rights for Kineret® and clinical data for Kepivance® from Amgen. This is a corporate announcement detailing a significant business transaction (acquisition of rights/data) and its financial implications, rather than a routine regulatory filing like a 10-K, an earnings release, or a dividend notice. It fits best under Capital/Financing Update (CAP) as it relates to changes in corporate assets and structure through acquisition, or potentially Regulatory Filings (RNS) if CAP is too specific for a general M&A announcement that isn't a formal takeover bid (TAR). Given the nature of acquiring rights and data, which impacts future capital deployment and asset base, CAP is a strong candidate. However, since it is a press release announcing a major corporate transaction (acquisition), it often falls under general corporate news. Since there is no specific 'M&A Activity' (TAR) code for asset/rights acquisition, and it is not a formal financing event (like issuing new shares), I will classify it as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that don't fit the other specific codes, although 'TAR' (M&A Activity) is often used broadly for transactions. Since this is an acquisition of assets/rights, not a merger/takeover bid, RNS is safer as a general announcement category, or I will re-evaluate against TAR. TAR is defined as 'Merger proposals or takeover bids'. This is an asset acquisition. Therefore, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a significant, non-standard corporate press release.
2013-09-09 Swedish
Sobi appoints Dennis Schmidt Pedersen as Senior Vice President Human Resources
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Senior Vice President of Human Resources, Dennis Schmidt Pedersen. This type of announcement concerns changes in senior management personnel. Reviewing the definitions, the 'Board/Management Information (Code: MANG)' category is defined as 'Announcement of changes in the company's board of directors or senior management.' This perfectly matches the content of the document.
2013-09-03 English
Sobi utser Dennis Schmidt Pedersen till personaldirektör
Board/Management Information Classification · 99% confidence The document is a press release dated September 3, 2013, announcing the appointment of Dennis Schmidt Pedersen as the new Chief Human Resources Officer (HR Director) for Swedish Orphan Biovitrum AB (Sobi). This content directly relates to changes in senior management personnel. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2013-09-03 Swedish
Sobi submits application for Orfadin® oral suspension to EMA
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Sobi has submitted an application for a new dosage form of Orfadin to the European Medicines Agency (EMA) and that the application has been validated. It contains company background information and contact details for media/investor relations. This type of announcement, which communicates a specific regulatory or operational event (like a submission validation) but is not a formal, comprehensive financial report (like 10-K, IR, or ER), fits best under the general 'Regulatory Filings' category, as it is a specific regulatory update that doesn't match the other defined categories (like DIRS, DIV, or CAP). Given its nature as a general corporate announcement about a regulatory step, RNS (Regulatory Filings) is the most appropriate fallback.
2013-08-22 English
Sobi lämnar in ansökan för en flytande formulering av Orfadin® till EMA
Regulatory Filings Classification · 99% confidence The document is a short press release from a pharmaceutical company (Sobi) announcing that they have submitted an application for a new formulation of their drug (Orfadin) to the European Medicines Agency (EMA). It details the submission, quotes management, and provides background on the drug and the company. This type of announcement, which is not a full financial report (like 10-K or IR), nor a management change (MANG), nor a dividend notice (DIV), nor a director's dealing (DIRS), fits best under the general category for regulatory or operational announcements that are not covered by more specific codes. Since it is a specific operational/regulatory update concerning a drug application, and it is not a standard financial filing, it is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update, but RNS serves as the best general regulatory announcement fallback when specific codes like LTR (Legal Proceedings) or CAP (Financing) do not apply. Given the context of a drug submission to a regulatory body (EMA), RNS is the most appropriate general regulatory announcement code.
2013-08-22 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter (Q2) of 2013 for Swedish Orphan Biovitrum AB (Sobi). It contains detailed financial statements, tables for revenue by product and region, management commentary (VD har ordet), and operational highlights. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2013
2013-07-18 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.